<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22216145</article-id><article-id pub-id-type="pmc">3245235</article-id><article-id pub-id-type="publisher-id">PONE-D-11-11780</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0028943</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Biotechnology</subject><subj-group><subject>Pharmacogenomics</subject></subj-group></subj-group><subj-group><subject>Computational Biology</subject><subj-group><subject>Genomics</subject><subj-group><subject>Pharmacogenomics</subject></subj-group></subj-group><subj-group><subject>Molecular Genetics</subject><subj-group><subject>Gene Duplication</subject><subject>Gene Identification and Analysis</subject><subject>Gene Expression</subject></subj-group></subj-group><subj-group><subject>Population Genetics</subject><subj-group><subject>Genetic Polymorphism</subject></subj-group></subj-group></subj-group><subj-group><subject>Evolutionary Biology</subject><subj-group><subject>Population Genetics</subject></subj-group></subj-group><subj-group><subject>Genetics</subject><subj-group><subject>Heredity</subject><subj-group><subject>Genotypes</subject></subj-group></subj-group><subj-group><subject>Molecular Genetics</subject><subj-group><subject>Gene Duplication</subject><subject>Gene Identification and Analysis</subject></subj-group></subj-group><subj-group><subject>Population Genetics</subject><subj-group><subject>Genetic Polymorphism</subject></subj-group></subj-group><subj-group><subject>Epigenetics</subject><subject>Gene Expression</subject><subject>Human Genetics</subject></subj-group></subj-group><subj-group><subject>Genomics</subject><subj-group><subject>Genomic Medicine</subject><subj-group><subject>Pharmacogenomics</subject></subj-group></subj-group><subj-group><subject>Pharmacogenomics</subject></subj-group></subj-group><subj-group><subject>Molecular Cell Biology</subject><subj-group><subject>Gene Expression</subject></subj-group></subj-group><subj-group><subject>Population Biology</subject><subj-group><subject>Population Genetics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Clinical Genetics</subject><subj-group><subject>Personalized Medicine</subject></subj-group></subj-group><subj-group><subject>Diagnostic Medicine</subject></subj-group><subj-group><subject>Drugs and Devices</subject><subj-group><subject>Pharmacokinetics</subject><subj-group><subject>Drug Metabolism</subject></subj-group></subj-group><subj-group><subject>Clinical Pharmacology</subject><subject>Pharmacoepidemiology</subject><subject>Pharmacogenetics</subject></subj-group></subj-group><subj-group><subject>Epidemiology</subject><subj-group><subject>Genetic Epidemiology</subject><subject>Pharmacoepidemiology</subject></subj-group></subj-group><subj-group><subject>Mental Health</subject><subj-group><subject>Therapies</subject><subj-group><subject>Drug Psychotherapy</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Identification of New Alleles and the Determination of Alleles and Genotypes Frequencies at the <italic>CYP2D6</italic> Gene in Emiratis</article-title><alt-title alt-title-type="running-head">Antidepressants and <italic>CYP2D6</italic> Polymorphism</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Qumsieh</surname><given-names>Rula Y.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ali</surname><given-names>Bassam R.</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Abdulrazzaq</surname><given-names>Yousef M.</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Osman</surname><given-names>Ossama</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Akawi</surname><given-names>Nadia A.</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bastaki</surname><given-names>Salim M. A.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>&#x0002a;</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Department of Pharmacology, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Department of Pathology, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Department of Pediatrics, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>Department of Psychiatry, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Zanger</surname><given-names>Ulrich M.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Germany</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>sbastaki@uaeu.ac.ae</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: SMAB BRA YMA OO. Performed the experiments: RYQ NAA OO. Analyzed the data: SMAB BRA YMA RYQ NAA. Contributed reagents/materials/analysis tools: RYQ OO. Wrote the paper: SMAB BRA YMA NAA RYQ. Designed the software used in the analysis: BRA NAA.</p></fn></author-notes><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>22</day><month>12</month><year>2011</year></pub-date><volume>6</volume><issue>12</issue><elocation-id>e28943</elocation-id><history><date date-type="received"><day>26</day><month>6</month><year>2011</year></date><date date-type="accepted"><day>17</day><month>11</month><year>2011</year></date></history><permissions><copyright-statement>Qumsieh et al.</copyright-statement><copyright-year>2011</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><p>CYP2D6 belongs to the cytochrome P450 superfamily of enzymes and plays an important role in the metabolism of 20&#x02013;25&#x00025; of clinically used drugs including antidepressants. It displays inter-individual and inter-ethnic variability in activity ranging from complete absence to excessive activity which causes adverse drug reactions and toxicity or therapy failure even at normal drug doses. This variability is due to genetic polymorphisms which form poor, intermediate, extensive or ultrarapid metaboliser phenotypes. This study aimed to determine <italic>CYP2D6</italic> alleles and their frequencies in the United Arab Emirates (UAE) local population. <italic>CYP2D6</italic> alleles and genotypes were determined by direct DNA sequencing in 151 Emiratis with the majority being psychiatric patients on antidepressants. Several new alleles have been identified and in total we identified seventeen alleles and 49 genotypes. <italic>CYP2D6&#x0002a;1</italic> (wild type) and <italic>CYP2D6&#x0002a;2</italic> alleles (extensive metaboliser phenotype) were found with frequencies of 39.1&#x00025; and 12.2&#x00025;, respectively. <italic>CYP2D6&#x0002a;41</italic> (intermediate metaboliser) occurred in 15.2&#x00025;. Homozygous <italic>CYP2D6&#x0002a;4</italic> allele (poor metaboliser) was found with a frequency of 2&#x00025; while homozygous and heterozygous <italic>CYP2D6&#x0002a;4</italic> occurred with a frequency of 9&#x00025;. <italic>CYP2D6&#x0002a;2xn</italic>, caused by gene duplication (ultrarapid metaboliser) had a frequency of 4.3&#x00025;. <italic>CYP2D6</italic> gene duplication/multiduplication occurred in 16&#x00025; but only 11.2&#x00025; who carried more than 2 active functional alleles were considered ultrarapid metabolisers. <italic>CYP2D6</italic> gene deletion in one copy occurred in 7.5&#x00025; of the study group. In conclusion, <italic>CYP2D6</italic> gene locus is heterogeneous in the UAE national population and no significant differences have been identified between the psychiatric patients and controls.</p></abstract><counts><page-count count="6"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Interethnic variation in the capacity to metabolize drugs is mainly due to genetic constitution <xref rid="pone.0028943-Bernard1" ref-type="bibr">[1]</xref>. Recent advances in pharmacogenomics elucidated that some variations in DNA sequences recognized as single nucleotide polymorphisms (SNPs) may explain some of the variability in drug metabolizing enzyme activities. These contribute to drug-induced adverse reactions, toxicity, and therapeutic responses in different ethnic groups <xref rid="pone.0028943-Ma1" ref-type="bibr">[2]</xref>. The best characterized genetically determined variations in antidepressant drug metabolism are those associated with the polymorphic N-acetyltransferase, NAT2, and two polymorphic cytochrome P450s involved with oxidation reactions, CYP2D6 and CYP2C19, all of which show marked interethnic differences in catalytic activity and allele distribution <xref rid="pone.0028943-Dahl1" ref-type="bibr">[3]</xref>. Whereas the clinical significance of the CYP2C19 polymorphism is uncertain, the clinical consequences of the CYP2D6 polymorphism are well established <xref rid="pone.0028943-Eichelbaum1" ref-type="bibr">[4]</xref>, <xref rid="pone.0028943-Kalow1" ref-type="bibr">[5]</xref>.</p><p>The potential importance of interethnic differences in <italic>CYP2D6</italic> gene structure and expression lies in the large number of drugs whose elimination is catalysed by CYP2D6. These include tricyclic antidepressants and antipsychotics <xref rid="pone.0028943-Dahl2" ref-type="bibr">[6]</xref>. The <italic>CYP2D6</italic> locus is highly polymorphic and currently more than 120 variant <italic>CYP2D6</italic> alleles have been described (<ext-link ext-link-type="uri" xlink:href="http://www.cypalleles.ki.se/cyp2d6.htm">www.cypalleles.ki.se/cyp2d6.htm</ext-link>). These alleles can be divided into; 1) alleles resulting in no functional product (poor metabolizers, PMs); 2) alleles causing a reduced rate of metabolism (intermediate metabolizers, IMs); 3) alleles causing ultrarapid metabolism (ultra-rapid metabolizers, UMs); and 4) alleles with no important functional consequences (extensive metabolizers, EMs) <xref rid="pone.0028943-Cascorbi1" ref-type="bibr">[7]</xref> Given the relatively wide spread use of CYP2D6-metabolised medications, including antidepressants, and limited availability of data regarding the alleles and genotypes in Emiratis, this study was undertaken to determine <italic>CYP2D6</italic> alleles and their frequencies, using direct DNA sequencing of the full coding regions and large parts of the intronic sequences, in this population.</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>Identification of new <italic>CYP2D6</italic> alleles</title><p>The DNA sequence analysis of all the coding regions, the splice sites and large parts of the intronic regions was carried out for 151 subjects from the UAE local population. This included 50 healthy controls and 101 subjects on antidepressants. Eight out of 151 subjects had new alleles and new genotypes (<xref ref-type="table" rid="pone-0028943-t001">Table 1</xref> and <xref ref-type="table" rid="pone-0028943-t002">2</xref>). <italic>CYP2D6&#x0002a;105</italic> was the only new homozygous genotype where we found a novel mutation c.1097T&#x0003e;C (g.3268T&#x0003e;C) which causes p.F366S change in the corresponding protein. This mutation is accompanied by the two common SNPs, namely p.R296C and p.S486T (<ext-link ext-link-type="uri" xlink:href="http://www.cypalleles.ki.se/cyp2d6.htm">http://www.cypalleles.ki.se/cyp2d6.htm</ext-link>) in a homozygous state. The other new alleles were unique in their combinations. Five patients were carrying unreported combinations of known SNPs with some unknowns (<xref ref-type="table" rid="pone-0028943-t002">Table 2</xref>). Both new SNPs g.1783 A&#x0003e;C and g.4028C&#x0003e;A were intronic thus their effect on the enzyme function is not clear. The ascertained haplotypes in these subjects were undetermined due to the heterozygosity of some of their SNPs. Parents were not included in this study and therefore it was not possible to assign the alleles.</p><table-wrap id="pone-0028943-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0028943.t001</object-id><label>Table 1</label><caption><title>New alleles found in <italic>CYP2D6</italic> among our UAE study group.</title></caption><alternatives><graphic id="pone-0028943-t001-1" xlink:href="pone.0028943.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">New Alleles</td><td align="left" rowspan="1" colspan="1">DNA change<xref ref-type="table-fn" rid="nt103">&#x000a5;</xref>
</td><td align="left" rowspan="1" colspan="1">Protein</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CYP2D6&#x0002a;102</td><td align="left" rowspan="1" colspan="1">Intron 1 conversion with CYP2D7 (214&#x02013;245); 310G&#x0003e;T; <bold>972C&#x0003e;T</bold>; 1661G&#x0003e;C; <bold>2850C&#x0003e;T</bold>; 3384A&#x0003e;C; 3790C&#x0003e;T; <bold>4180G&#x0003e;C</bold>; 4481G&#x0003e;A</td><td align="left" rowspan="1" colspan="1">A90V; R296C; S486T</td></tr><tr><td align="left" rowspan="1" colspan="1">CYO2D6&#x0002a;103</td><td align="left" rowspan="1" colspan="1">Intron 1 conversion with CYP2D7 (214&#x02013;245); 310G&#x0003e;T;<bold>972C&#x0003e;T</bold>;1661G&#x0003e;C;<bold>1749A&#x0003e;G</bold>;<bold>2850C&#x0003e;T</bold>; 3384A&#x0003e;C; 3790C&#x0003e;T; <bold>4180G&#x0003e;C</bold>; 4481G&#x0003e;A</td><td align="left" rowspan="1" colspan="1">A90V; N166D; R296C; S486T</td></tr><tr><td align="left" rowspan="1" colspan="1">CYP2D6&#x0002a;104</td><td align="left" rowspan="1" colspan="1">Intron 1 conversion with CYP2D7 (214&#x02013;245); 310G&#x0003e;T; 843T&#x0003e;G; 1661G&#x0003e;C; <bold>1720A&#x0003e;T</bold>; <bold>2850C&#x0003e;T</bold>; 3384A&#x0003e;C; 3790C&#x0003e;T; <bold>4180G&#x0003e;C</bold>; 4481G&#x0003e;A</td><td align="left" rowspan="1" colspan="1">E156A; R296C; S486T</td></tr><tr><td align="left" rowspan="1" colspan="1">CYP2D6&#x0002a;105</td><td align="left" rowspan="1" colspan="1">Intron 1 conversion with CYP2D7 (214&#x02013;245); 310G&#x0003e;T; 746C&#x0003e;G; 843T&#x0003e;G; 1661G&#x0003e;C; <bold>2850C&#x0003e;T</bold>; <bold><underline>3268T&#x0003e;C</underline></bold>; 3384A&#x0003e;C; 3790C&#x0003e;T; <bold>4180G&#x0003e;C</bold>; 4481G&#x0003e;A</td><td align="left" rowspan="1" colspan="1">R296C; <bold><underline>F366S</underline></bold>; S486T</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>Nucleotide variations in <bold>bold</bold> are the major SNPs/alterations responsible for the phenotype of the corresponding allele.</p></fn><fn id="nt102"><label/><p>Nucleotide and amino acid variations <underline>underlined</underline> are novel and have not been reported previously in the <italic>CYP2D6</italic> allele nomenclature database.</p></fn><fn id="nt103"><label>&#x000a5;</label><p>All nucleotide changes are based on Genbank accession number M33388&#x0002a; following the instructions in database <ext-link ext-link-type="uri" xlink:href="http://www.cypalleles.ki.se/cyp2d6.htm">http://www.cypalleles.ki.se/cyp2d6.htm</ext-link>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0028943-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0028943.t002</object-id><label>Table 2</label><caption><title>New genotypes found in <italic>CYP2D6</italic> among our UAE study group.</title></caption><alternatives><graphic id="pone-0028943-t002-2" xlink:href="pone.0028943.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">New Genotypes</td><td align="left" rowspan="1" colspan="1">DNA change<xref ref-type="table-fn" rid="nt106">&#x000a5;</xref>
</td><td align="left" rowspan="1" colspan="1">Protein change</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Genotype 1</td><td align="left" rowspan="1" colspan="1">Homozygous SNPs: Intron 1 conversion with CYP2D7 (214&#x02013;245); 310G&#x0003e;T; 843T&#x0003e;G; 1661G&#x0003e;C; <bold>2850C&#x0003e;T</bold>; 3384A&#x0003e;C; 3790C&#x0003e;T; <bold>4180G&#x0003e;C</bold>. Heterozygous SNPs: <bold>984A&#x0003e;G/A</bold>; 2661G&#x0003e;A/G; <underline>4028C&#x0003e;A/C</underline>
</td><td align="left" rowspan="1" colspan="1">H94R; R296C; S486T</td></tr><tr><td align="left" rowspan="1" colspan="1">Genotype 2</td><td align="left" rowspan="1" colspan="1">Homozygous SNPs:310G&#x0003e;T. Heterozygous SNPs <bold>2606G&#x0003e;A/G</bold>; <bold>2610T&#x0003e;A/T</bold>
</td><td align="left" rowspan="1" colspan="1">E278K; M279K</td></tr><tr><td align="left" rowspan="1" colspan="1">Genotype 3</td><td align="left" rowspan="1" colspan="1">Homozygous SNPs: 310G&#x0003e;T; 1661G&#x0003e;C; <bold>3183G&#x0003e;A</bold>; 3384A&#x0003e;C; <bold>4180G&#x0003e;C</bold>. Heterozygous SNPs: <bold>100C&#x0003e;T/C</bold>; 1039C&#x0003e;T/C; <bold>2850C&#x0003e;T/C</bold>; 4401C&#x0003e;T/C</td><td align="left" rowspan="1" colspan="1">P34S; R296C; V338M; S486T</td></tr><tr><td align="left" rowspan="1" colspan="1">Genotype 4</td><td align="left" rowspan="1" colspan="1">Homozygous SNPs: 310G&#x0003e;T; 1661G&#x0003e;C; <bold>2850C&#x0003e;T</bold>; 3384A&#x0003e;C; 3790C&#x0003e;T; <bold>4180G&#x0003e;C</bold>; 4481G&#x0003e;A. Heterozygous SNPs: Intron 1 conversion with CYP2D7(214&#x02013;245);<bold>1749A&#x0003e;G/A</bold>; <underline>1783A&#x0003e;C/A</underline>; <bold>2988G&#x0003e;A/G</bold>
</td><td align="left" rowspan="1" colspan="1">N166D; R296C; Splicing defect; S486T</td></tr><tr><td align="left" rowspan="1" colspan="1">Genotype 5</td><td align="left" rowspan="1" colspan="1">Homozygous SNPs: 4481G&#x0003e;AHeterozygous SNPs: Intron 1 conversion with CYP2D7 (214&#x02013;245); 310G&#x0003e;T/G; 843T&#x0003e;G/T; 1661G&#x0003e;C/G; <bold>1749 A&#x0003e;C/A</bold>; <underline>1783 A&#x0003e;C/A</underline>; <bold>2850C&#x0003e;T/C</bold>; 3384A&#x0003e;C/A; 3790C&#x0003e;T/C; <bold>4180G&#x0003e;C/G</bold>
</td><td align="left" rowspan="1" colspan="1">N166D; R296C; S486T</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt104"><label/><p>Nucleotide variations in <bold>bold</bold> are the major SNPs/alterations responsible for the phenotype of the corresponding allele.</p></fn><fn id="nt105"><label/><p>Nucleotide and amino acid variations <underline>underlined</underline> are not reported in <italic>CYP2D6</italic> allele nomenclature database.</p></fn><fn id="nt106"><label>&#x000a5;</label><p>All nucleotide change is based on Gene M33388&#x0002a; following the database<ext-link ext-link-type="uri" xlink:href="http://www.cypalleles.ki.se/cyp2d6.htm">http://www.cypalleles.ki.se/cyp2d6.htm</ext-link>.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2b"><title>
<italic>CYP2D6</italic> allele frequencies among 151 Emiratis</title><p>Within our sequenced study group (<italic>n</italic>&#x0200a;=&#x0200a;151, 302 alleles) 17 different alleles were identified in which <italic>CYP2D6&#x0002a;1</italic> occurred in the highest frequency of 39.1&#x00025; (<italic>n</italic>&#x0200a;=&#x0200a;118) (<xref ref-type="table" rid="pone-0028943-t003">Table 3</xref>). This was followed by <italic>CYP2D6&#x0002a;41</italic> with a frequency of 15.2&#x00025; (<italic>n</italic>&#x0200a;=&#x0200a;46), while <italic>CYP2D6&#x0002a;2</italic>, <italic>CYP2D6&#x0002a;4</italic>, <italic>CYP2D6&#x0002a;2xn</italic>, <italic>CYP2D6&#x0002a;39</italic> and <italic>CYP2D6&#x0002a;10</italic> had frequencies of 12.2&#x00025;, 9&#x00025;, 4.3&#x00025;, 4&#x00025; and 3.3&#x00025;, respectively.</p><table-wrap id="pone-0028943-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0028943.t003</object-id><label>Table 3</label><caption><title>
<italic>CYP2D6</italic> allele frequencies among 151 (302 alleles) UAE nationals.</title></caption><alternatives><graphic id="pone-0028943-t003-3" xlink:href="pone.0028943.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Alleles presence as homozygous or heterozygous</td><td align="left" rowspan="1" colspan="1">Allele frequency &#x00025;. N&#x0200a;=&#x0200a;151. 302 alleles total</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic>CYP2D6&#x0002a;1</italic>
</td><td align="left" rowspan="1" colspan="1">39.1</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>CYP2D6&#x0002a;41</italic>
</td><td align="left" rowspan="1" colspan="1">15.2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>CYP2D6&#x0002a;2</italic>
</td><td align="left" rowspan="1" colspan="1">12.2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>CYP2D6&#x0002a;4</italic>
</td><td align="left" rowspan="1" colspan="1">9</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>CYP2D6&#x0002a;2xn</italic>
</td><td align="left" rowspan="1" colspan="1">4.3</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>CYP2D6&#x0002a;39</italic>
</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>CYP2D6&#x0002a;10</italic>
</td><td align="left" rowspan="1" colspan="1">3.3</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>CYP2D6&#x0002a;New</italic>
</td><td align="left" rowspan="1" colspan="1">2.6</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>CYP2D6&#x0002a;35</italic>
</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>CYP2D6&#x0002a;17</italic>
</td><td align="left" rowspan="1" colspan="1">2.5</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>CYP2D6&#x0002a;29</italic>
</td><td align="left" rowspan="1" colspan="1">1.60</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>CYP2D6&#x0002a;1xn</italic>
</td><td align="left" rowspan="1" colspan="1">1.60</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>CYP2D6&#x0002a;34</italic>
</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>CYP2D6&#x0002a;27</italic>
</td><td align="left" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>CYP2D6&#x0002a;10xn</italic>
</td><td align="left" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>CYP2D6&#x0002a;43</italic>
</td><td align="left" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>CYP2D6&#x0002a;46</italic>
</td><td align="left" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Total</italic>
</td><td align="left" rowspan="1" colspan="1">100&#x00025;</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="s2c"><title>Frequencies of <italic>CYP2D6</italic> functional alleles among 151 UAE individuals</title><p>As shown in <xref ref-type="table" rid="pone-0028943-t004">table 4</xref> there were only 3 (2&#x00025;) individuals out of 151 who carried no functional alleles at all. Of the 151 subjects, 27 (17.9&#x00025;) had only one active allele. The majority carried two active alleles with a frequency of 68.9&#x00025;, whereas 17 (11.3&#x00025;) individuals were carrying more than two active alleles.</p><table-wrap id="pone-0028943-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0028943.t004</object-id><label>Table 4</label><caption><title>The number of active alleles in the sample studied (<italic>n&#x0200a;=&#x0200a;151</italic>).</title></caption><alternatives><graphic id="pone-0028943-t004-4" xlink:href="pone.0028943.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Number of active alleles</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">&#x00025;</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">0 active alleles</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">1 active allele</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">17.9</td></tr><tr><td align="left" rowspan="1" colspan="1">2 active alleles</td><td align="left" rowspan="1" colspan="1">104</td><td align="left" rowspan="1" colspan="1">68.9</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;2 active alleles</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">11.3</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="s2d"><title>Frequency of <italic>CYP2D6</italic> Genotypes and their predicted phenotypes</title><p>
<italic>CYP2D6&#x0002a;1</italic>, <italic>CYP2D6&#x0002a;2</italic> and <italic>CYP2D6&#x0002a;39</italic> encode for EMs phenotype in both homozygous and heterozygous forms. <italic>CYP2D6&#x0002a;10</italic> and <italic>CYP2D6&#x0002a;41</italic> encode for IMs phenotype but only in the homozygous form or when it is combined with one of the poor metaboliser alleles such as <italic>CYP2D6&#x0002a;4</italic> which only encode for a PM phenotype in the homozygous form <xref rid="pone.0028943-Masimirembwa1" ref-type="bibr">[8]</xref>&#x02013;<xref rid="pone.0028943-Broly1" ref-type="bibr">[10]</xref>. <italic>CYP2D6&#x0002a;2xn</italic> which indicates the presence of gene duplication encode for a UMs phenotype <xref rid="pone.0028943-Hosono1" ref-type="bibr">[11]</xref>.</p><p>In addition to the new genotypes described in <xref ref-type="table" rid="pone-0028943-t002">table 2</xref>, we found 44 different already known genotypes among our study group (<xref ref-type="table" rid="pone-0028943-t005">Table 5</xref>). Twenty three out of the 44 genotypes were assigned under EMs phenotype (homozygous or heterozygous). Twelve out of the 44 were genotypes associated with duplication or multiduplication in one of their alleles and they were assigned under UMs phenotype. Eight out of 44 genotypes were assigned as IMs phenotype. One genotype was predicted to have PM phenotype.</p><table-wrap id="pone-0028943-t005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0028943.t005</object-id><label>Table 5</label><caption><title>The observed distribution of <italic>CYP2D6</italic> known genotypes and their predicted phenotypes in the recruited individuals (<italic>n</italic>&#x0200a;=&#x0200a;151).</title></caption><alternatives><graphic id="pone-0028943-t005-5" xlink:href="pone.0028943.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">
<italic>#</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>CYP2D6</italic> genotype</td><td align="left" rowspan="1" colspan="1">Predicted phenotype</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">&#x00025;</td><td align="left" rowspan="1" colspan="1">No of active alleles</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>1</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;1/&#x0002a;1(wild type)</td><td align="left" rowspan="1" colspan="1">Homozygous EM</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">20.5</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>2</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;1/&#x0002a;1xn</td><td align="left" rowspan="1" colspan="1">Homozygous UM</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>3</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;1/&#x0002a;2</td><td align="left" rowspan="1" colspan="1">Heterozygous EM</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">11.3</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>4</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;1/&#x0002a;2xn</td><td align="left" rowspan="1" colspan="1">Heterozygous UM</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">3.3</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>5</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;2/&#x0002a;2</td><td align="left" rowspan="1" colspan="1">Homozygous EM</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>6</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;2xn/&#x0002a;2</td><td align="left" rowspan="1" colspan="1">Homozygous UM</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>7</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;2/&#x0002a;4</td><td align="left" rowspan="1" colspan="1">Heterozygous EM</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>8</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;2xn/&#x0002a;4</td><td align="left" rowspan="1" colspan="1">Heterozygous EM</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>9</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;2/&#x0002a;41</td><td align="left" rowspan="1" colspan="1">Heterozygous EM</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>10</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;2xn/&#x0002a;41</td><td align="left" rowspan="1" colspan="1">Heterozygous UM</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>11</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;2/&#x0002a;39</td><td align="left" rowspan="1" colspan="1">Heterozygous EM</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">2.6</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>12</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;2xn/&#x0002a;39</td><td align="left" rowspan="1" colspan="1">Heterozygous UM</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>13</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;2xn/&#x0002a;10</td><td align="left" rowspan="1" colspan="1">Heterozygous UM</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>14</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;2xn/&#x0002a;17</td><td align="left" rowspan="1" colspan="1">Heterozygous UM</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>15</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;2/&#x0002a;29</td><td align="left" rowspan="1" colspan="1">Heterozygous EM</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>16</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;1/&#x0002a;41</td><td align="left" rowspan="1" colspan="1">Heterozygous EM</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">9.3</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>17</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;1xn/&#x0002a;41</td><td align="left" rowspan="1" colspan="1">Heterozygous UM</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>18</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;1/&#x0002a;4</td><td align="left" rowspan="1" colspan="1">Heterozygous EM</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">5.3</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>19</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;1/&#x0002a;35</td><td align="left" rowspan="1" colspan="1">Heterozygous EM</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>20</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;1/10</td><td align="left" rowspan="1" colspan="1">Heterozygous EM</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>21</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;1xn/10</td><td align="left" rowspan="1" colspan="1">Heterozygous UM</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>22</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;1/&#x0002a;34</td><td align="left" rowspan="1" colspan="1">Heterozygous EM</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>23</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;1/&#x0002a;17</td><td align="left" rowspan="1" colspan="1">Heterozygous EM</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>24</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;1/&#x0002a;27</td><td align="left" rowspan="1" colspan="1">Heterozygous EM</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>25</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;1xn/&#x0002a;27</td><td align="left" rowspan="1" colspan="1">Heterozygous UM</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>26</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;1/&#x0002a;29</td><td align="left" rowspan="1" colspan="1">Heterozygous EM</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>27</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;1xn/&#x0002a;39</td><td align="left" rowspan="1" colspan="1">Heterozygous UM</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>28</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;1/&#x0002a;46</td><td align="left" rowspan="1" colspan="1">Heterozygous EM</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>29</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;4/&#x0002a;4</td><td align="left" rowspan="1" colspan="1">Homozygous PM</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>30</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;4/&#x0002a;41</td><td align="left" rowspan="1" colspan="1">Heterozygous IM</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>31</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;4/&#x0002a;29</td><td align="left" rowspan="1" colspan="1">Heterozygous IM</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>32</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;4/&#x0002a;43</td><td align="left" rowspan="1" colspan="1">Heterozygous EM</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>33</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;41/&#x0002a;41</td><td align="left" rowspan="1" colspan="1">Homozygous IM</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">5.3</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>34</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;35/&#x0002a;35</td><td align="left" rowspan="1" colspan="1">Homozygous EM</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>35</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;10/&#x0002a;10</td><td align="left" rowspan="1" colspan="1">Homozygous IM</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>36</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;29/&#x0002a;29</td><td align="left" rowspan="1" colspan="1">Homozygous IM</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>37</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;17/&#x0002a;17</td><td align="left" rowspan="1" colspan="1">Homozygous IM</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>38</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;17/&#x0002a;41</td><td align="left" rowspan="1" colspan="1">Heterozygous IM</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>39</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;17/&#x0002a;39</td><td align="left" rowspan="1" colspan="1">Heterozygous EM</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>40</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;10/&#x0002a;41</td><td align="left" rowspan="1" colspan="1">Heterozygous IM</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>41</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;10xn/&#x0002a;41</td><td align="left" rowspan="1" colspan="1">Heterozygous UM</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>42</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;10/&#x0002a;35</td><td align="left" rowspan="1" colspan="1">Heterozygous EM</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>43</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;35/&#x0002a;39</td><td align="left" rowspan="1" colspan="1">Heterozygous EM</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>44</bold>
</td><td align="left" rowspan="1" colspan="1">&#x0002a;39/&#x0002a;41</td><td align="left" rowspan="1" colspan="1">Heterozygous EM</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">2</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt107"><label/><p>
<italic>EM</italic> extensive metabolizer, <italic>PM</italic> poor metabolizer, <italic>UM</italic> ultrarapid metabolizer and <italic>IM</italic> intermediate metabolizer.</p></fn></table-wrap-foot></table-wrap><p>In the subjects studied (<italic>n</italic>&#x0200a;=&#x0200a;151) the following <italic>CYP2D6</italic> genotypes were identified with the highest occurrence:<italic>&#x0002a;1/&#x0002a;1</italic>(<italic>n</italic>&#x0200a;=&#x0200a;31),<italic>&#x0002a;1/&#x0002a;2</italic> (<italic>n</italic>&#x0200a;=&#x0200a;17),<italic>&#x0002a;1/&#x0002a;41</italic>(<italic>n</italic>&#x0200a;=&#x0200a;14),<italic>&#x0002a;1/&#x0002a;4</italic>(<italic>n</italic>&#x0200a;=&#x0200a;8), <italic>&#x0002a;41/&#x0002a;41</italic>(<italic>n</italic>&#x0200a;=&#x0200a;8), <italic>&#x0002a;4/&#x0002a;41</italic> (<italic>n</italic>&#x0200a;=&#x0200a;6), <italic>&#x0002a;2/&#x0002a;39</italic> (<italic>n</italic>&#x0200a;=&#x0200a;4) and <italic>&#x0002a;1/&#x0002a;2xn</italic> (<italic>n</italic>&#x0200a;=&#x0200a;5) (<xref ref-type="table" rid="pone-0028943-t005">Table 5</xref>). Out of the 151 study group 2&#x00025; (<italic>n</italic>&#x0200a;=&#x0200a;3) were poor metabolizers carrying the <italic>&#x0002a;4/&#x0002a;4</italic> genotype.</p></sec></sec><sec id="s3"><title>Discussion</title><p>The impact of CYP2D6 polymorphisms on the clinical outcome of psychoactive drugs has been extensively described in the literature <xref rid="pone.0028943-IngelmanSundberg1" ref-type="bibr">[12]</xref>. CYP2D6 has more than 120 allelic variants resulting from point mutations, rearrangements, additions, deletions and duplications. Several studies have shown that the frequencies of the alternative CYP2D6 phenotypes vary significantly among different ethnic groups <xref rid="pone.0028943-Ma1" ref-type="bibr">[2]</xref>, <xref rid="pone.0028943-Evans1" ref-type="bibr">[13]</xref>, <xref rid="pone.0028943-Bertilsson1" ref-type="bibr">[14]</xref>. Examples of these ethnically specific markers are <italic>CYP2D6&#x0002a;17</italic>, found in Africans, and <italic>CYP2D6&#x0002a;10</italic>, found in Asians. Both result in slower metabolism of CYP2D6 substrates (such as risperidone and paroxetine), which result in higher plasma concentrations thereby needing lower doses for therapeutic effect <xref rid="pone.0028943-Masimirembwa1" ref-type="bibr">[8]</xref>, <xref rid="pone.0028943-IngelmanSundberg1" ref-type="bibr">[12]</xref>, <xref rid="pone.0028943-Johansson1" ref-type="bibr">[15]</xref>, <xref rid="pone.0028943-Matimba1" ref-type="bibr">[16]</xref>.</p><p>Duplications or multiplications of the <italic>CYP2D6</italic> gene occurs in 1&#x00025; of Swedes, 5&#x00025; of Spanish, 29&#x00025; of Ethiopians and 19&#x00025; of Arabs results in an increased number of enzymes available for metabolic processes <xref rid="pone.0028943-Dahl1" ref-type="bibr">[3]</xref>, <xref rid="pone.0028943-Cascorbi1" ref-type="bibr">[7]</xref>, <xref rid="pone.0028943-McLellan1" ref-type="bibr">[17]</xref>. This is called ultrarapid metabolization. Patients with these mutations will require higher doses of medications to achieve the therapeutic response. UMs were previously regarded as &#x0201c;noncompliant&#x0201d; because they did not respond to the standard medication doses administered <xref rid="pone.0028943-Kawanishi1" ref-type="bibr">[18]</xref>. <italic>CYP2D6</italic> genotypic frequency information had been determined for most populations around the world <xref rid="pone.0028943-IngelmanSundberg1" ref-type="bibr">[12]</xref>. They displayed significant interethnic differences in <italic>CYP2D6</italic> allele frequencies <xref rid="pone.0028943-Bernard1" ref-type="bibr">[1]</xref> resulting in variable percentages of PMs, IMs, EMs and UMs in a given population. This is the first study to genotype <italic>CYP2D6</italic> gene in UAE local population. However, the incidence of different <italic>CYP2D6</italic> polymorphisms in the UAE population holds a great challenge to be characterized because of the huge ethnic diversity that exists in the country.</p><p>The novel variant p.F366S found in this population has not been reported elsewhere and its clinical impact is unknown, but theoretically and based on bioinformatics tools it could be clinically significant. It changed phenylalanine which is a hydrophobic large amino acid into serine which is a polar uncharged small amino acid. The phenyl ring on the phenylalanine probably interacts with the beta sheet and changes it into small hydrophilic molecule thus disrupting the reaction and the structure (<xref ref-type="fig" rid="pone-0028943-g001">Figure 1</xref>). Moreover, this amino acid substitution is predicted to probably be protein damaging based on analysis using PolyPhen program for prediction of functional effect of human SNPs (<ext-link ext-link-type="uri" xlink:href="http://genetics.bwh.harvard.edu/pph/">http://genetics.bwh.harvard.edu/pph/</ext-link>). Unfortunately, no plasma was available for the homozygous subject, thus we were unable to determine his metabolic ratio (MR).</p><fig id="pone-0028943-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0028943.g001</object-id><label>Figure 1</label><caption><title>CYP2D6 protein showing position 366 where there is a substitution from phenylalanine to serine amino acid.</title><p>Molecular modeling was performed using RasMol (<ext-link ext-link-type="uri" xlink:href="http://www.openrasmol.org">http://www.openrasmol.org</ext-link>). A) 366 Phenylalanine is large hydrophobic amino acid B) 366 Serine is a polar uncharged small Amino acid.</p></caption><graphic xlink:href="pone.0028943.g001"/></fig><p>
<italic>CYP2D6</italic> allele frequencies in our UAE study group were compared with frequencies seen in other ethnic populations. According to Toscano et al. <xref rid="pone.0028943-Toscano1" ref-type="bibr">[19]</xref>
<italic>1</italic>,<italic>&#x0002a;2</italic> and<italic>&#x0002a;41</italic> are the three most frequent <italic>CYP2D6</italic> functional alleles. This is similar to our findings as the said alleles occurred in the highest frequencies namely: <italic>&#x0002a;1</italic> (39.1&#x00025;), <italic>&#x0002a;41</italic> (15.2&#x00025;) and <italic>&#x0002a;2</italic> (12.2&#x00025;). Unlike other populations <xref rid="pone.0028943-Toscano1" ref-type="bibr">[19]</xref>, <italic>CYP2D6&#x0002a;41</italic> occurred more frequently than <italic>CYP2D6&#x0002a;2</italic> in UAE. In the Croatian population the frequencies of polymorphic <italic>CYP2D6</italic>&#x0002a;2,&#x0002a;3, &#x0002a;4,&#x0002a; 5, and &#x0002a; 6 alleles were 4&#x00025;, 2.8&#x00025;, 14&#x00025;, 1&#x00025;, and 1.5&#x00025;, respectively. The most frequently observed null allele was <italic>CYP2D6&#x0002a;4</italic>, which accounted for 72&#x00025; of all null alleles. Among the Croatian population studied, 60&#x00025; of the subjects had EM genotype, 33&#x00025; were IMs, and 3&#x00025; exhibited the PM genotype. Four percent exhibited the UM genotype due to amplified <italic>CYP2D6</italic> gene (<italic>CYP2D6&#x0002a;2</italic> allele) <xref rid="pone.0028943-Bozina1" ref-type="bibr">[20]</xref>. The allele frequency of <italic>CYP2D6&#x0002a;4</italic>; the most common defective allele among Caucasians (25&#x00025;); was 14&#x00025; in Croatians <xref rid="pone.0028943-Bozina1" ref-type="bibr">[20]</xref> and only 3.5&#x00025; in the Saudi population <xref rid="pone.0028943-McLellan2" ref-type="bibr">[21]</xref> and 2&#x00025; in the UAE population. Two other alleles, <italic>CYP2D6&#x0002a;10</italic> (47&#x02013;70&#x00025; in Asians) and <italic>CYP2D6&#x0002a;17</italic> (25&#x02013;40&#x00025; in blacks), are common in certain populations resulting in diminished enzyme activity. Both were found only at low frequencies of 3.0&#x00025; each in the Saudi Arabian population <xref rid="pone.0028943-McLellan2" ref-type="bibr">[21]</xref> and 3.3&#x00025; and 2.5&#x00025; respectively, in the UAE population.</p><p>PMs alleles (e.g.&#x0002a;3,&#x0002a;4,&#x0002a;4<italic>xn</italic>,&#x0002a;5,&#x0002a;6,&#x0002a;7,&#x0002a;8,&#x0002a;11 or &#x0002a;45) cause absent enzymatic activity and, possibly, an increased risk of adverse drug reactions even with routine therapy with <italic>CYP2D6</italic> substrates. <italic>CYP2D6</italic>&#x0002a;3,&#x0002a;4,&#x0002a;5,&#x0002a;6 form 93&#x02013;97&#x00025; of the PM phenotypes in Caucasians while other inactivating alleles form less than 1&#x00025; <xref rid="pone.0028943-Marez1" ref-type="bibr">[22]</xref>, <xref rid="pone.0028943-Sachse1" ref-type="bibr">[23]</xref>. <italic>CYP2D6&#x0002a;4</italic> is the most common defective allele in Caucasians with a frequency of 20&#x02013;25&#x00025; in both heterozygous and homozygous forms but only homozygous <italic>CYP2D6&#x0002a;4</italic> is associated with the PM phenotype <xref rid="pone.0028943-Zanger1" ref-type="bibr">[24]</xref>. Heterozygous and homozygous <italic>CYP2D6&#x0002a;4</italic> were found with a frequency of 9&#x00025; in the Emirati population which is similar to the Palestinians (7.8&#x00025;) <xref rid="pone.0028943-Sistonen1" ref-type="bibr">[25]</xref> and a bit lower than the Croatians (14&#x00025;) <xref rid="pone.0028943-Bozina1" ref-type="bibr">[20]</xref> but not as high as what was reported in other Caucasians <xref rid="pone.0028943-IngelmanSundberg1" ref-type="bibr">[12]</xref>, <xref rid="pone.0028943-Zanger1" ref-type="bibr">[24]</xref>. Three individuals (2&#x00025;) were homozygous for <italic>CYP2D6&#x0002a;4</italic> and were categorized as being PMs. Other defective alleles such as (&#x0002a;3,&#x0002a;5 and&#x0002a;6) could not be detected perhaps due to the small sample size (<italic>n</italic>&#x0200a;=&#x0200a;151) we used for genotyping. Because of the fact that patients with <italic>CYP2D6&#x0002a;4</italic> are PMs they are more than likely to develop side effects with normal doses of CYP2D&#x0002a;6-dependent antidepressants, particularly because most of these drugs have narrow therapeutic windows. Therefore drugs like tricyclic antidepressants (TCAs), which have a narrow therapeutic window and venalaxine are going to pose problems in these patients. Therefore lower doses to approximately half the therapeutic doses of TCA are recommended <xref rid="pone.0028943-DeLeon1" ref-type="bibr">[26]</xref>, <xref rid="pone.0028943-Kirchheiner1" ref-type="bibr">[27]</xref>. The opposite is true of UMs who need higher doses of CYP2D6-dependent drugs to reach therapeutic levels.</p><p>Individuals were considered as IMs if they had one <italic>CYP2D6</italic> allele with a decreased enzyme activity (&#x0002a;9,&#x0002a;10,&#x0002a;17,&#x0002a;29 or &#x0002a;41) together with a non-functional allele (e.g. &#x0002a;3,&#x0002a;4,&#x0002a;4<italic>xn</italic>,&#x0002a;5,&#x0002a;6,&#x0002a;7,&#x0002a;8 or &#x0002a;11) <xref rid="pone.0028943-Sachse1" ref-type="bibr">[23]</xref> or if they had two partially functional alleles. Among the 17 variant <italic>CYP2D6</italic> alleles that were found in the UAE population, <italic>CYP2D6&#x0002a;41</italic> allele had a high frequency of 15.2&#x00025; which is higher than what was reported in other Caucasians (8.5&#x00025;) <xref rid="pone.0028943-Bernard1" ref-type="bibr">[1]</xref>, while closer to what was reported in Palestinians (12.7&#x00025;) <xref rid="pone.0028943-Sistonen1" ref-type="bibr">[25]</xref>. <italic>CYP2D6&#x0002a;41</italic> occurs in 22&#x00025; of Ethiopians <xref rid="pone.0028943-Aklillu1" ref-type="bibr">[28]</xref>. In Asia (1&#x00025;) and Africa (1&#x02013;2&#x00025;), it occurs in a lower frequency than in Caucasians (10&#x00025;) <xref rid="pone.0028943-DeLeon1" ref-type="bibr">[26]</xref>. <italic>CYP2D6&#x0002a;41/&#x0002a;null</italic> form nearly 50&#x02013;70&#x00025; of all Caucasian IMs <xref rid="pone.0028943-Zanger2" ref-type="bibr">[29]</xref>. In this study group 4.6&#x00025; had <italic>CYP2D6&#x0002a;41/&#x0002a;null (&#x0002a;41/&#x0002a;4)</italic> genotype while 8.6&#x00025; had <italic>CYP2D6&#x0002a;IM/&#x0002a;IM</italic> (e.g.<italic>&#x0002a;41/&#x0002a;41</italic>, <italic>&#x0002a;10/&#x0002a;10</italic>,<italic>&#x0002a;10/&#x0002a;41</italic> and <italic>&#x0002a;17/&#x0002a;17</italic>). <italic>CYP2D6&#x0002a;10</italic> and <italic>&#x0002a;17</italic> cause a decrease in the enzyme activity. The frequency of <italic>CYP2D6&#x0002a;10</italic> is relatively high in Asia (51&#x00025;) and therefore nearly 25&#x00025; of Asians are classified as IMs <xref rid="pone.0028943-IngelmanSundberg1" ref-type="bibr">[12]</xref>. Black Africans and African-Americans have high frequencies of <italic>CYP2D6&#x0002a;17</italic> allele (up to 35&#x00025;) and that is the reason why the majority of them are IMs <xref rid="pone.0028943-Matimba1" ref-type="bibr">[16]</xref>. On the other hand, null alleles are much rarer in Asia and Africa than in Caucasians <xref rid="pone.0028943-Bernard1" ref-type="bibr">[1]</xref>. <italic>CYP2D6&#x0002a;10</italic> and <italic>CYP2D6&#x0002a;17</italic> were found in UAE at a low frequencies of 3.3&#x00025; and 2&#x00025; respectively, and this was expected as they occurred in even lower frequencies in some other Caucasians.</p><p>UMs are characterized by faster rate of drug metabolism caused by the presence of multiple active functional <italic>CYP2D6</italic> genes (at least 3 copies) on one individual allele. Consequently these subjects do not reach the therapeutic plasma levels even at normal drug doses. Alleles with multiple gene copies were found in high frequencies only in some regions such as Saudi Arabia (21&#x00025;) <xref rid="pone.0028943-McLellan2" ref-type="bibr">[21]</xref> and Ethiopia (29&#x00025;) <xref rid="pone.0028943-Aklillu1" ref-type="bibr">[28]</xref>, while in the rest of the world the frequencies do not exceed 10&#x00025; <xref rid="pone.0028943-DeLeon1" ref-type="bibr">[26]</xref>, <xref rid="pone.0028943-Kouhi1" ref-type="bibr">[30]</xref>. In UAE, the most common duplicated alleles are &#x0002a;1 and &#x0002a;2 where <italic>CYP2D6&#x0002a;2xn</italic> occurred in 4.3&#x00025; which is close to Palestinian's frequency (4.9&#x00025;) <xref rid="pone.0028943-Sistonen1" ref-type="bibr">[25]</xref> and to other Caucasians (1&#x02013;5&#x00025;), while higher than Asians and Africans (0&#x02013;2&#x00025;) but still lower than Saudi Arabians and African Ethiopians (10&#x02013;16&#x00025;) <xref rid="pone.0028943-Cascorbi1" ref-type="bibr">[7]</xref>. <italic>CYP2D6&#x0002a;1xn</italic> occurred only in 1.6&#x00025; of the Emiratis while it reached 3.7&#x00025; in some Middle Eastern regions <xref rid="pone.0028943-Sistonen1" ref-type="bibr">[25]</xref>.</p><p>Kouhi et al. <xref rid="pone.0028943-Kouhi1" ref-type="bibr">[30]</xref> determined the frequency of four <italic>CYP2D6</italic> alleles in Iran. He found that <italic>CYP2D6&#x0002a;2</italic> that encode for an EM phenotype occurred in a frequency of 32&#x00025; which when compared to what we found in UAE (12.2&#x00025;) is considered high. <italic>CYP2D6&#x0002a;4</italic> occurred in 12.5&#x00025; of Iranians and this is somehow close to the frequency in UAE (9&#x00025;). <italic>CYP2D6&#x0002a;10</italic> occurred more frequently in Iran (9&#x00025;) than in UAE (3.3&#x00025;) while CYP2D6<italic>&#x0002a;17</italic> was completely absent in Iran with a 2&#x00025; frequency in UAE nationals. In addition, Iran has more PMs (4&#x00025;) than UAE (2&#x00025;), while they were 8&#x00025; in Palestinians, 17&#x00025; in Jews of Russian origin, and 0&#x00025; in Jews of Yemeni and Ethiopian extraction <xref rid="pone.0028943-Britzi1" ref-type="bibr">[31]</xref>.</p><p>In conclusion, <italic>CYP2D6</italic> gene can be considered a challenge for genotyping because its polymorphisms are numerous including not only SNPs but also gene duplication and deletion. However, our approach of direct DNA sequencing of all the coding regions and most of the intronic noncoding regions provided us with the opportunity to capture most of the variants. Our study showed that <italic>CYP2D6</italic> is polymorphic in the UAE population with a different distribution compared with other populations but there were some similarities especially with Palestinians. New SNPs, New alleles and atypical genotypes were observed in the UAE study group (<xref ref-type="table" rid="pone-0028943-t001">Table 1</xref> and <xref ref-type="table" rid="pone-0028943-t002">2</xref>). Expanding the number of participants and further studies are anticipated to enrich the <italic>CYP2D6</italic> nomenclature database and increase our knowledge of CYP2D6 among Emiratis. In addition, we believe that family based studies would be helpful in determining the full haplotypes in this population. MRs especially for the new alleles should be measured to verify the corresponding phenotype.</p></sec><sec sec-type="materials|methods" id="s4"><title>Materials and Methods</title><sec id="s4a"><title>Subjects blood sampling</title><sec id="s4a1"><title>Ethics Statement</title><p>This study was approved by Al-Ain District Human Research Ethics and the Faculty of Medicine and Health Sciences, UAE University Committee (07/148) and informed consent was obtained from all subjects.</p><p>Blood samples were collected from 151 Emiratis: 101 of them were unrelated UAE nationals who suffered from endogenous depression and were being treated with antidepressants at Al Ain Hospital inpatient and outpatient psychiatry clinics as well as Tawam Hospital outpatient clinic. The other 50 individuals were blood donors randomly selected from healthy population.</p></sec></sec><sec id="s4b"><title>Extraction of DNA</title><p>DNA was extracted from peripheral leukocytes using a whole-blood Qiagen extraction kit (Flexigene DNA isolation kit). The isolated genomic DNA samples were kept in sterile plastic vials at 4&#x000b0;C until analysis or stored at &#x02212;20&#x000b0;.</p></sec><sec id="s4c"><title>PCR amplification of the <italic>CYP2D</italic> gene and DNA sequencing</title><p>Primer design and PCR amplification was achieved under standard conditions described by Masimirembwa et al. (1996) <xref rid="pone.0028943-Masimirembwa1" ref-type="bibr">[8]</xref>. The oligonucleotides used for PCR are listed in <xref ref-type="supplementary-material" rid="pone.0028943.s001">table S1</xref>. DNA was sequenced using the BigDye Terminator kit v3.1with a 3130x/genetic analyzer system (Applied Biosystems) following ExoSAP-IT&#x000ae; (USB Corporation) treatment of the PCR products. Cycle sequencing was performed under standard conditions recommended by the manufacturers (Applied Biosystems Inc.). Oligonucleotides used for sequencing are listed in <xref ref-type="supplementary-material" rid="pone.0028943.s002">table S2</xref>.</p></sec><sec id="s4d"><title>Analysis of sequencing data</title><p>For each patient the produced sequences were aligned with the original <italic>CYP2D6</italic> sequence (NM_000106.4) using ClustalW2 (<ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/Tools/msa/clustalw2/">http://www.ebi.ac.uk/Tools/msa/clustalw2/</ext-link>) to detect the presence of SNPs or mutations as well as to define each patient's genotype. Expasy Translate tool (<ext-link ext-link-type="uri" xlink:href="http://us.expasy.org/tools/dna.html">http://us.expasy.org/tools/dna.html</ext-link>) was used to translate DNA sequences into their protein sequences to examine the influence of the DNA changes at the protein level and thus the enzymatic activity.</p></sec><sec id="s4e"><title>TaqMan RT-PCR</title><p>
<italic>CYP2D6 gene</italic> copy number was determined using TaqMan&#x000ae; real-time quantitative PCR (ABI 7900 Fast Real-Time PCR system; Applied Biosystems). Real time data were collected by the SDS 2.1 software, and data were analyzed using the relative quantification (&#x00394;&#x00394;C<sub>T</sub>) method. Three calibrators (containing one, two or three <italic>CYP2D6</italic> gene copies DNA samples from Coriell Inc., <ext-link ext-link-type="uri" xlink:href="http://ccr.coriell.org">http://ccr.coriell.org</ext-link>) were included in each run for the accuracy of the results and each sample was normalized to RNaseP to produce &#x00394;C<sub>T</sub>. All samples were then normalized to the calibrator (NA17120) sample to determine &#x00394;&#x00394;C<sub>T</sub>. Relative quantity (RQ) values were then calculated and multiplied by 2 to produce <italic>CYP2D6</italic> gene copy number.</p></sec><sec id="s4f"><title>Statistical analysis</title><p>The statistical analysis was conducted by SPSS 17.0 (for windows) to calculate frequencies. The level of significant of <italic>P</italic> value was set at less than 0.05.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0028943.s001"><label>Table S1</label><caption><p>
<bold>Primers for PCR amplification of </bold>
<bold><italic>CYP2D6</italic></bold>
<bold> gene (exons 1&#x02013;9).</bold>
</p><p>(DOCX)</p></caption><media xlink:href="pone.0028943.s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0028943.s002"><label>Table S2</label><caption><p>
<bold>Primers for </bold>
<bold><italic>CYP2D6</italic></bold>
<bold> sequencing.</bold>
</p><p>(DOCX)</p></caption><media xlink:href="pone.0028943.s002.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We thank the subjects and clinicians involved in this study.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This research has been funded by UAE University through grant no. 02-04-8-11/08. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group><ref-list><title>References</title><ref id="pone.0028943-Bernard1"><label>1</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bernard</surname><given-names>S</given-names></name><name><surname>Neville</surname><given-names>KA</given-names></name><name><surname>Nguyen</surname><given-names>AT</given-names></name><name><surname>Flockhart</surname><given-names>DA</given-names></name></person-group>
<year>2006</year>
<article-title>Interethnic Differences in Genetic Polymorphisms of CYP2D6 in the U.S.</article-title>
<source>Population: Clinical Implications Oncologist</source>
<volume>11</volume>
<fpage>126</fpage>
<lpage>135</lpage>
<pub-id pub-id-type="pmid">16476833</pub-id></element-citation></ref><ref id="pone.0028943-Ma1"><label>2</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ma</surname><given-names>MK</given-names></name><name><surname>Woo</surname><given-names>MH</given-names></name><name><surname>McLeod</surname><given-names>HL</given-names></name></person-group>
<year>2002</year>
<article-title>Genetic basis of drug metabolism.</article-title>
<source>Am J Health Syst Pharm</source>
<volume>59</volume>
<fpage>2061</fpage>
<lpage>2069</lpage>
<pub-id pub-id-type="pmid">12434718</pub-id></element-citation></ref><ref id="pone.0028943-Dahl1"><label>3</label><element-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Dahl</surname><given-names>ML</given-names></name><name><surname>Bertilsson</surname><given-names>L</given-names></name><name><surname>Chang</surname><given-names>M</given-names></name><name><surname>Roh</surname><given-names>HK</given-names></name><name><surname>Aden Abdi</surname><given-names>Y</given-names></name><etal/></person-group>
<year>1995</year>
<article-title>Genetic contribution to interethnic variations in drug oxidation.</article-title>
<person-group person-group-type="editor"><name><surname>Alv&#x000e1;n</surname><given-names>G</given-names></name><name><surname>Balant</surname><given-names>LP</given-names></name><name><surname>Bechtel</surname><given-names>PR</given-names></name><name><surname>Boobis</surname><given-names>AR</given-names></name><name><surname>Gram</surname><given-names>LF</given-names></name><name><surname>Paintaud</surname><given-names>G</given-names></name><name><surname>Pithan</surname><given-names>K</given-names></name></person-group>
<source>COST B1 Conference on Variability and Specificity in Drug Metabolism</source>
<fpage>111</fpage>
<lpage>124</lpage>
<comment>(European Commission, Luxembourg)</comment>
</element-citation></ref><ref id="pone.0028943-Eichelbaum1"><label>4</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eichelbaum</surname><given-names>M</given-names></name><name><surname>Gross</surname><given-names>AS</given-names></name></person-group>
<year>1990</year>
<article-title>The genetic polymorphism of debrisoquine/sparteine metabolism-clinical aspects.</article-title>
<source>Pharmacol Ther</source>
<volume>46</volume>
<fpage>377</fpage>
<lpage>394</lpage>
<pub-id pub-id-type="pmid">2188269</pub-id></element-citation></ref><ref id="pone.0028943-Kalow1"><label>5</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kalow</surname><given-names>W</given-names></name></person-group>
<year>2005</year>
<article-title>A pharmacogeneticist's look at drug effects and the drug development process: an overview.</article-title>
<source>Expert Opin Pharmacother</source>
<volume>6</volume>
<issue>8</issue>
<fpage>1299</fpage>
<lpage>1303</lpage>
<pub-id pub-id-type="pmid">16013980</pub-id></element-citation></ref><ref id="pone.0028943-Dahl2"><label>6</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dahl</surname><given-names>M-L</given-names></name><name><surname>Bertilsson</surname><given-names>L</given-names></name></person-group>
<year>1993</year>
<article-title>Genetically variable metabolism of antidepressants and neuroleptic drugs in man.</article-title>
<source>Pharmacogenetics</source>
<volume>3</volume>
<fpage>61</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="pmid">8100166</pub-id></element-citation></ref><ref id="pone.0028943-Cascorbi1"><label>7</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cascorbi</surname><given-names>I</given-names></name></person-group>
<year>2003</year>
<article-title>Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication.</article-title>
<source>Eur J Clin Invest</source>
<volume>33</volume>
<issue>suppl 2</issue>
<fpage>17</fpage>
<lpage>22</lpage>
</element-citation></ref><ref id="pone.0028943-Masimirembwa1"><label>8</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Masimirembwa</surname><given-names>C</given-names></name><name><surname>Persson</surname><given-names>I</given-names></name><name><surname>Bertilsson</surname><given-names>L</given-names></name><name><surname>Hasler</surname><given-names>J</given-names></name><name><surname>Ingelman-Sundberg</surname><given-names>M</given-names></name></person-group>
<year>1996</year>
<article-title>A novel mutant variant of the CYP2D6 gene (CYP2D6&#x0002a;17) common in a black African population: association with diminished debrisoquine hydroxylase activity.</article-title>
<source>Br J Clin Pharmacol</source>
<volume>42</volume>
<fpage>713</fpage>
<lpage>719</lpage>
<pub-id pub-id-type="pmid">8971426</pub-id></element-citation></ref><ref id="pone.0028943-Daly1"><label>9</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Daly</surname><given-names>AK</given-names></name><name><surname>Armstrong</surname><given-names>M</given-names></name><name><surname>Monkman</surname><given-names>SC</given-names></name><name><surname>Idle</surname><given-names>ME</given-names></name><name><surname>Idle</surname><given-names>JR</given-names></name></person-group>
<year>1991</year>
<article-title>Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.</article-title>
<source>Pharmacogenetics</source>
<volume>1</volume>
<fpage>33</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="pmid">1688241</pub-id></element-citation></ref><ref id="pone.0028943-Broly1"><label>10</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Broly</surname><given-names>F</given-names></name><name><surname>Gaedigk</surname><given-names>A</given-names></name><name><surname>Heim</surname><given-names>M</given-names></name><name><surname>Eichelbaum</surname><given-names>M</given-names></name><name><surname>Morike</surname><given-names>K</given-names></name><etal/></person-group>
<year>1991</year>
<article-title>Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.</article-title>
<source>DNA Cell Biol</source>
<volume>10</volume>
<fpage>545</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="pmid">1681816</pub-id></element-citation></ref><ref id="pone.0028943-Hosono1"><label>11</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hosono</surname><given-names>N</given-names></name><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Kiyotani</surname><given-names>K</given-names></name><name><surname>Mushiroda</surname><given-names>T</given-names></name><name><surname>Takata</surname><given-names>S</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>CYP2D6 Genotyping for Functional-Gene Dosage Analysis by Allele Copy Number Detection.</article-title>
<source>Clinical Chemistry</source>
<volume>55</volume>
<fpage>1546</fpage>
<lpage>1554</lpage>
<pub-id pub-id-type="pmid">19541866</pub-id></element-citation></ref><ref id="pone.0028943-IngelmanSundberg1"><label>12</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ingelman-Sundberg</surname><given-names>M</given-names></name></person-group>
<year>2005</year>
<article-title>Genetic polymorphism of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity.</article-title>
<source>Pharmacogenetics J</source>
<volume>5</volume>
<fpage>6</fpage>
<lpage>13</lpage>
</element-citation></ref><ref id="pone.0028943-Evans1"><label>13</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Evans</surname><given-names>WE</given-names></name><name><surname>Relling</surname><given-names>MV</given-names></name></person-group>
<year>2004</year>
<article-title>Moving towards individualized medicine with pharmacogenomics.</article-title>
<source>Nature</source>
<volume>429</volume>
<fpage>464</fpage>
<lpage>468</lpage>
<pub-id pub-id-type="pmid">15164072</pub-id></element-citation></ref><ref id="pone.0028943-Bertilsson1"><label>14</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bertilsson</surname><given-names>L</given-names></name></person-group>
<year>1995</year>
<article-title>Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.</article-title>
<source>Clin Pharmacokinet</source>
<volume>29</volume>
<fpage>192</fpage>
<lpage>209</lpage>
<pub-id pub-id-type="pmid">8521680</pub-id></element-citation></ref><ref id="pone.0028943-Johansson1"><label>15</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Johansson</surname><given-names>I</given-names></name><name><surname>Oscarson</surname><given-names>M</given-names></name><name><surname>Yue</surname><given-names>QY</given-names></name><name><surname>Bertilsson</surname><given-names>L</given-names></name><name><surname>Sj&#x000f6;qvist</surname><given-names>F</given-names></name><etal/></person-group>
<year>1994</year>
<article-title>Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.</article-title>
<source>Mol Pharmacol</source>
<volume>46</volume>
<issue>3</issue>
<fpage>452</fpage>
<lpage>459</lpage>
<pub-id pub-id-type="pmid">7935325</pub-id></element-citation></ref><ref id="pone.0028943-Matimba1"><label>16</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matimba</surname><given-names>A</given-names></name><name><surname>Del-Favero</surname><given-names>J</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name><name><surname>Masimirembwa</surname><given-names>C</given-names></name></person-group>
<year>2009</year>
<article-title>Novel variants of major drug-metabolising genes in diverse African population and their predicted functional effects.</article-title>
<source>Hum Genomics</source>
<volume>3</volume>
<issue>2</issue>
<fpage>169</fpage>
<lpage>190</lpage>
<pub-id pub-id-type="pmid">19164093</pub-id></element-citation></ref><ref id="pone.0028943-McLellan1"><label>17</label><element-citation publication-type="other">
<person-group person-group-type="author"><name><surname>McLellan</surname><given-names>RA</given-names></name><name><surname>Oscarson</surname><given-names>M</given-names></name><name><surname>Seidegard</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>DAP</given-names></name><name><surname>Ingelman-Sundberg</surname><given-names>M</given-names></name></person-group>
<year>1996</year>
<article-title>genotype analysis of cytochrome P450D26 in a Saudi Arabian population. XI<sup>th</sup> International Symposium on microsomes and drug oxidation.</article-title>
<comment>Los Angeles, CA; P-205</comment>
</element-citation></ref><ref id="pone.0028943-Kawanishi1"><label>18</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kawanishi</surname><given-names>C</given-names></name><name><surname>Lundgren</surname><given-names>S</given-names></name><name><surname>Agren</surname><given-names>H</given-names></name><name><surname>Bertilsson</surname><given-names>L</given-names></name></person-group>
<year>2004</year>
<article-title>Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study.</article-title>
<source>Eur J Clin Pharmacol</source>
<volume>59</volume>
<fpage>803</fpage>
<lpage>807</lpage>
<pub-id pub-id-type="pmid">14652703</pub-id></element-citation></ref><ref id="pone.0028943-Toscano1"><label>19</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Toscano</surname><given-names>C</given-names></name><name><surname>Klein</surname><given-names>K</given-names></name><name><surname>Blievernicht</surname><given-names>J</given-names></name><name><surname>Schaeffeler</surname><given-names>E</given-names></name><name><surname>Saussele</surname><given-names>T</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Impaired expression of CYP2D6 in intermediate metabolizers carrying the &#x0002a;41 allele caused by the intronic SNP 2988G&#x0003e;A: evidence for modulation of splicing events.</article-title>
<source>Pharmacogenet Genomics</source>
<volume>16</volume>
<fpage>755</fpage>
<lpage>766</lpage>
<pub-id pub-id-type="pmid">17001295</pub-id></element-citation></ref><ref id="pone.0028943-Bozina1"><label>20</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bozina</surname><given-names>N</given-names></name><name><surname>Granic</surname><given-names>P</given-names></name><name><surname>Lalic</surname><given-names>Z</given-names></name><name><surname>Tramisak</surname><given-names>I</given-names></name><name><surname>Lovric</surname><given-names>M</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>Genetic Polymorphisms of Cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian Population.</article-title>
<source>Croatian Med J</source>
<volume>44</volume>
<fpage>425</fpage>
<lpage>428</lpage>
</element-citation></ref><ref id="pone.0028943-McLellan2"><label>21</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McLellan</surname><given-names>RA</given-names></name><name><surname>Oscarson</surname><given-names>M</given-names></name><name><surname>Seideg&#x000e5;rd</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>DA</given-names></name><name><surname>Ingelman-Sundberg</surname><given-names>M</given-names></name></person-group>
<year>1997</year>
<article-title>Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians.</article-title>
<source>Pharmacogenetic</source>
<volume>7</volume>
<fpage>187</fpage>
<lpage>191</lpage>
</element-citation></ref><ref id="pone.0028943-Marez1"><label>22</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marez</surname><given-names>D</given-names></name><name><surname>Legrand</surname><given-names>M</given-names></name><name><surname>Sabbagh</surname><given-names>N</given-names></name><name><surname>Lo Guidice</surname><given-names>JM</given-names></name><name><surname>Spire</surname><given-names>C</given-names></name><etal/></person-group>
<year>1997</year>
<article-title>Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution.</article-title>
<source>Pharmacogenetics</source>
<volume>7</volume>
<fpage>193</fpage>
<lpage>202</lpage>
<pub-id pub-id-type="pmid">9241659</pub-id></element-citation></ref><ref id="pone.0028943-Sachse1"><label>23</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sachse</surname><given-names>C</given-names></name><name><surname>Brockmoller</surname><given-names>J</given-names></name><name><surname>Hildebrand</surname><given-names>M</given-names></name><name><surname>Muller</surname><given-names>K</given-names></name><name><surname>Roots</surname><given-names>I</given-names></name></person-group>
<year>1998</year>
<article-title>Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizes of debrisoquine.</article-title>
<source>Pharmacogenetics</source>
<volume>8</volume>
<fpage>181</fpage>
<lpage>185</lpage>
<pub-id pub-id-type="pmid">10022755</pub-id></element-citation></ref><ref id="pone.0028943-Zanger1"><label>24</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zanger</surname><given-names>UM</given-names></name><name><surname>Hofmann</surname><given-names>MH</given-names></name></person-group>
<year>2008</year>
<article-title>Polymorphic cytochrome P450 CYP2B6 and CYP2D&#x02227;: recent advances on single nucleotide polymorphisms affecting slicing.</article-title>
<source>Acta Chimica Slovenica</source>
<volume>55</volume>
<fpage>38</fpage>
<lpage>44</lpage>
</element-citation></ref><ref id="pone.0028943-Sistonen1"><label>25</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sistonen</surname><given-names>J</given-names></name><name><surname>Sajantila</surname><given-names>A</given-names></name><name><surname>Oscar</surname><given-names>L</given-names></name><name><surname>Corander</surname><given-names>J</given-names></name><name><surname>Barbujani</surname><given-names>G</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure.</article-title>
<source>Pharmacogenet Genomics</source>
<volume>17</volume>
<fpage>93</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="pmid">17301689</pub-id></element-citation></ref><ref id="pone.0028943-DeLeon1"><label>26</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Leon</surname><given-names>J</given-names></name><name><surname>Armstrong</surname><given-names>SC</given-names></name><name><surname>Cozza</surname><given-names>KL</given-names></name></person-group>
<year>2006</year>
<article-title>Clinical guidelines for psychiatrics for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.</article-title>
<source>Psychosomatics</source>
<volume>47</volume>
<fpage>75</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="pmid">16384813</pub-id></element-citation></ref><ref id="pone.0028943-Kirchheiner1"><label>27</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kirchheiner</surname><given-names>J</given-names></name><name><surname>Nickchen</surname><given-names>K</given-names></name><name><surname>Bauer</surname><given-names>M</given-names></name><name><surname>Wong</surname><given-names>ML</given-names></name><name><surname>Licinio</surname><given-names>J</given-names></name><etal/></person-group>
<year>2004</year>
<article-title>Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.</article-title>
<source>Mol Psychiatry</source>
<volume>9</volume>
<fpage>442</fpage>
<lpage>473</lpage>
<pub-id pub-id-type="pmid">15037866</pub-id></element-citation></ref><ref id="pone.0028943-Aklillu1"><label>28</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aklillu</surname><given-names>E</given-names></name><name><surname>Persson</surname><given-names>I</given-names></name><name><surname>Bertilsson</surname><given-names>L</given-names></name><name><surname>Johansson</surname><given-names>I</given-names></name><name><surname>Rodrigues</surname><given-names>F</given-names></name><etal/></person-group>
<year>1996</year>
<article-title>Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.</article-title>
<source>J Pharmacol Exp Ther</source>
<volume>278</volume>
<fpage>441</fpage>
<lpage>446</lpage>
<pub-id pub-id-type="pmid">8764380</pub-id></element-citation></ref><ref id="pone.0028943-Zanger2"><label>29</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zanger</surname><given-names>UM</given-names></name><name><surname>Raimundo</surname><given-names>S</given-names></name><name><surname>Eichelbaum</surname><given-names>M</given-names></name></person-group>
<year>2004</year>
<article-title>Cytochrome P450 2D6: overview and update on pharmacology, genetics, and biochemistry.</article-title>
<source>Naunyn Schmiedebergs Arch Pharmacol</source>
<volume>369</volume>
<fpage>23</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="pmid">14618296</pub-id></element-citation></ref><ref id="pone.0028943-Kouhi1"><label>30</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kouhi</surname><given-names>H</given-names></name><name><surname>Hamzeiy</surname><given-names>H</given-names></name><name><surname>Barar</surname><given-names>J</given-names></name><name><surname>Asadi</surname><given-names>M</given-names></name><name><surname>Omidi</surname><given-names>Y</given-names></name></person-group>
<year>2009</year>
<article-title>Frequency of Five Important CYP2D6 Alleles within an Iranian Population (Eastern Azerbaijan).</article-title>
<source>Genet Test Mol Biomarkers</source>
<volume>13</volume>
<fpage>665</fpage>
<lpage>670</lpage>
<pub-id pub-id-type="pmid">19715474</pub-id></element-citation></ref><ref id="pone.0028943-Britzi1"><label>31</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Britzi</surname><given-names>M</given-names></name><name><surname>Bialer</surname><given-names>M</given-names></name><name><surname>Arcavi</surname><given-names>L</given-names></name><name><surname>Schacbari</surname><given-names>A</given-names></name><name><surname>Kapitulnik</surname><given-names>T</given-names></name><etal/></person-group>
<year>2000</year>
<article-title>Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups.</article-title>
<source>Ther Drug Monit</source>
<volume>22</volume>
<fpage>510</fpage>
<lpage>516</lpage>
<pub-id pub-id-type="pmid">11034254</pub-id></element-citation></ref></ref-list></back></article>